This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furberg, C. D. Articles by Pitt, B. Search for Related Content PubMed PubMed Citation Articles by Furberg, C. D. Articles by Pitt, B.

VIEWPOINT

Are all angiotensin-converting enzyme inhibitors interchangeable?

Curt D. Furberg, MD, PhD^* and Bertram Pitt, MD, FACC

^* Department of Public Health Sciences, Wake Forest University, Winston-Salem, North Carolina, USA
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

Manuscript received August 24, 2000; revised manuscript received December 6, 2000, accepted December 27, 2000.

Reprint requests and correspondence: Dr. Curt D. Furberg, Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157
cfurberg{at}wfubmc.edu

In the treatment of most medical conditions, there are many choices. A critical question for practicing clinicians is: "Are all drugs within a class interchangeable?" In the past decade, the market has seen a proliferation of drugs within popular drug classes. The original drugs within a class typically have better scientific documentation than the newer ones, which are often referred to as "me-too" drugs. Due to a lesser financial investment, the latter may be available at a lower cost. Good reasons exist for grouping drugs, however, there is no accepted definition of the term "class effect." Although members of a drug class share main actions, they may have clinically important differences in terms of efficacy and safety. There are many such examples in the literature. This article reviews the class effect concept as it applies to the angiotensin-converting enzyme (ACE) inhibitors. Only half of the 10 ACE inhibitors available in the U.S. have been shown to improve survival and reduce morbidity in patients with heart failure or myocardial infarction. It is unknown whether the other five have the same safety and efficacy profiles or what their optimal doses are. Thus, we do not know whether all ACE inhibitors are fully interchangeable. The practice of medicine ought to be based on solid scientific evidence, not on assumptions or extrapolations. For our patients, such practice is a legitimate expectation. Therefore, it seems prudent to recommend that patients requiring ACE inhibitor therapy be prescribed one that has been proven effective and safe.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   CONSENSUS = Cooperative North Scandinavian Enalapril Survival Study   CHF = congestive heart failure   SOLVD = Studies Of Left Ventricular Dysfunction

This article has been cited by other articles:

				P. J. Hauptman All clinical trials are not created equal: The dilemma of HEAAL Eur J Heart Fail, September 1, 2008; 10(9): 817 - 818. [Full Text] [PDF]

				G. Salanti, J. P. Higgins, A. Ades, and J. P. Ioannidis Evaluation of networks of randomized trials Statistical Methods in Medical Research, June 1, 2008; 17(3): 279 - 301. [Abstract] [PDF]

				L. Pilote MD PhD, M. Abrahamowicz PhD, M. Eisenberg MD MPH, K. Humphries DSc, H. Behlouli MSc PhD, and J. V. Tu MD PhD Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure Can. Med. Assoc. J., May 6, 2008; 178(10): 1303 - 1311. [Abstract] [Full Text] [PDF]

				C. D. Furberg and B. M. Psaty Should Evidence-Based Proof of Drug Efficacy Be Extrapolated to a "Class of Agents"? Circulation, November 25, 2003; 108(21): 2608 - 2610. [Full Text] [PDF]

				J. P. Ruiz, L. M. Medina, F. M. Parra, J. M. de la Higuera Torres-Puchol, R. S. MacWalter, S. Y.S. Wong, K. Y.K. Wong, and A. D. Struthers Stroke Prevention: Indapamide, a Forgotten Option? * Response Stroke, September 1, 2003; 34(9): e156 - e157. [Full Text] [PDF]

				K. Tu, M. M. Mamdani, R. M. Jacka, N. J. Forde, D. M. Rothwell, and J. V. Tu The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario Can. Med. Assoc. J., March 4, 2003; 168(5): 553 - 557. [Abstract] [Full Text] [PDF]

				P. A McCullough, K. R Sandberg, J. Yee, and M. P Hudson Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 188 - 191. [Abstract] [PDF]

				H. L. Kennedy and R. S. Rosenson Physicians' interpretation of "class effects": A need for thoughtful re-evaluation J. Am. Coll. Cardiol., July 3, 2002; 40(1): 19 - 26. [Abstract] [Full Text] [PDF]